GlassScriptPhysician profile
Richard Douglas Alling
NPI 1366443202
$932.60
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $54.41 · 2021: $136 · 2022: $160 · 2023: $354 · 2024: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $358.05 | 2019-2024 | Arexvy, Shingrix, Boostrix |
| Exact Sciences Corporation | $130.78 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $120.19 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.85 | 2021-2023 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $83.82 | 2020-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $34.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.75 | 2019-2020 | |
| Abbott Laboratories | $24.07 | 2023 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $16.69 | 2022 | |
| Gilead Sciences, INC. | $15.66 | 2021 | |
| Dynavax Technologies Corporation | $14.87 | 2024 | Heplisav-B |
| Lilly USA, LLC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Alling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.